- Home
- WOK vs ALXO Comparison
WOK vs ALXO Comparison
Compare WOK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOK
- ALXO
- Stock Information
- Founded
- WOK 2002
- ALXO 2015
- Country
- WOK China
- ALXO United States
- Employees
- WOK N/A
- ALXO N/A
- Industry
- WOK
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- WOK
- ALXO Health Care
- Exchange
- WOK NYSE
- ALXO Nasdaq
- Market Cap
- WOK 79.5M
- ALXO 76.5M
- IPO Year
- WOK 2024
- ALXO 2020
- Fundamental
- Price
- WOK $4.97
- ALXO $2.02
- Analyst Decision
- WOK
- ALXO Strong Buy
- Analyst Count
- WOK 0
- ALXO 5
- Target Price
- WOK N/A
- ALXO $13.25
- AVG Volume (30 Days)
- WOK 161.9K
- ALXO 1.1M
- Earning Date
- WOK 02-03-2025
- ALXO 11-07-2024
- Dividend Yield
- WOK N/A
- ALXO N/A
- EPS Growth
- WOK N/A
- ALXO N/A
- EPS
- WOK N/A
- ALXO N/A
- Revenue
- WOK $9,863,642.00
- ALXO N/A
- Revenue This Year
- WOK N/A
- ALXO N/A
- Revenue Next Year
- WOK N/A
- ALXO N/A
- P/E Ratio
- WOK N/A
- ALXO N/A
- Revenue Growth
- WOK N/A
- ALXO N/A
- 52 Week Low
- WOK $3.26
- ALXO $1.19
- 52 Week High
- WOK $8.45
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- WOK N/A
- ALXO 60.32
- Support Level
- WOK N/A
- ALXO $1.40
- Resistance Level
- WOK N/A
- ALXO $1.88
- Average True Range (ATR)
- WOK 0.00
- ALXO 0.19
- MACD
- WOK 0.00
- ALXO 0.02
- Stochastic Oscillator
- WOK 0.00
- ALXO 81.15
About WOK WORK MEDICAL TECHNOLOGY GROUP LTD
WORK Medical Technology Group Ltd is a manufacturer of medical devices, and it is committed to providing professional and reliable medical devices to the world.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.